21 November 2016 - GSK and Innoviva today announced the filing by GSK of a regulatory submission with the US FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD). 

This follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018.

The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2-adrenergic agonist, delivered once-daily in GSK’s Ellipta dry powder inhaler.

The US regulatory submission of the closed triple therapy comprises a new drug application for the maintenance treatment of patients with COPD, including chronic bronchitis and emphysema. It is based on data from the closed triple combination therapy development programme, as well as data from studies with FF, UMEC and VI either alone or in combination.

Read GSK press release